ABTHERA ADVANCE Dressing is the next generation temporary abdominal closure device leveraging the technology and success of ABTHERA Open Abdomen Negative Pressure Therapy in bridging abdominal wall openings where primary closure is not possible and/or repeat abdominal entries are necessary.

The ABTHERA ADVANCE Dressing demonstrated significant increase in overall tissue, skin and fascia movement, with no change in intra-abdominal pressure in a comparative study in the United States of healthy pigs with an open abdominal wound which were treated with either ABTHERA SENSAT.R.A.C OA Dressing or ABTHERA ADVANCE Dressing at -125mmHg.1

“Expanding the KCI portfolio in markets outside the United States to offer new solutions for surgeons managing a variety of incision types is a key focus for the Company, as we strive to deliver new ways for patients to heal,” said R. Andrew Eckert, Chief Executive Officer of KCI. “The ABTHERA ADVANCE Open Abdomen Dressing has already shown tremendous potential for clinicians managing challenging open abdomens, and we look forward to meeting a need by making this therapy broadly available to European healthcare providers caring for some of their most compromised patients.”

The ABTHERA ADVANCE Perforated Foam collapses medially while under negative pressure, actively drawing wound edges together. ABTHERA ADVANCE Dressing is designed to manage the open abdomen by: Actively removing fluid and reducing bowel edema,   providing medial tension, which helps minimize fascial retraction and loss of domain, providing a separation between the abdominal wall and viscera, protecting abdominal contents, protecting abdominal contents from the external environment, allowing for rapid re-entry with no requirements for sutures for placement.

Clinical evidence demonstrates that ABTHERA Therapy is associated with improved outcomes, including improved primary fascial closure rates and a reduction in hospital stays when compared to Barker’s vacuum-packing technique (BVPT). In one open label, prospective observational study of 168 patients (111 ABTHERA Therapy vs. 57 BVPT), ABTHERA Therapy patients had a higher 30-day primary fascial closure rate (69% for ABTHERA Therapy vs. 51% for BVPT; p=0.03) and had a reduction in 30-day all-cause mortality compared to patients who received BVPT (14% ABTHERA Therapy vs. 30% BVPT; p=0.01).2

“Open abdomens after surgery can create a host of complex problems and complications, including infections and fistula,” said Ron Silverman, M.D., F.A.C.S., Chief Medical Officer, KCI. “Currently, options for effectively managing challenging open abdomens are limited. The ability to address many of the challenges associated with open abdomens with ABTHERA Therapy is a vital consideration when treating some of the most critically ill patients.”

Source: Company Press Release.